HANGZHOU TIANMUSHAN PHARMACEUTICAL ENTERPRISE CO.,LTD

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd

600671

CNE000000BF3

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
8.89 ^CNY	+4.59%		+11.82%	-23.76%

Apr. 26	Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 15	Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Qingdao Yuanjia Medical Treatment Technology Co., Ltd. completed the acquisition of 12.36% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd.

October 12, 2023

Qingdao Yuanjia Medical Treatment Technology Co., Ltd. agreed to acquire 12.36% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHSE:600671) from Yongxin Huarui Cultural Development Co., Ltd. for CNY140 million on August 18, 2023. In similar transaction Qingdao Huilong Huaze Investment Co., Ltd. agreed to acquire 7.98% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHSE:600671) from Yongxin Huarui Cultural Development Co., Ltd. for CNY90 million.

Qingdao Yuanjia Medical Treatment Technology Co., Ltd. completed the acquisition of 12.36% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHSE:600671) from Yongxin Huarui Cultural Development Co., Ltd. on October 13, 2023.

Latest news about Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 15	CI
Qingdao Yuanjia Medical Treatment Technology proposal of Adding Sheng Xiaofan to the Company's Eleventh Board of Directors to Hangzhou TianMuShan Pharmaceutical Enterprise was approved.	23-10-30	CI
On October 19, 2023 Qingdao Yuanjia Medical Treatment Technology propose of Adding Sheng Xiaofan to the Company's Eleventh Board of Directors to Hangzhou TianMuShan Pharmaceutical Enterprise.	23-10-19	CI
TianMuShan Pharma Elects Chairman	23-10-16	MT
Qingdao Yuanjia Medical Treatment Technology Co., Ltd. completed the acquisition of 12.36% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd.	23-10-12	CI
Qingdao Huilong Huaze Investment Co., Ltd. completed the acquisition of 7.98% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd.	23-10-12	CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-10	CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
TianMuShan Pharmaceutical CFO Steps Down	23-08-21	MT
Qingdao Huilong Huaze Investment Co., Ltd. agreed to acquire 7.98% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd. for CNY 90 million.	23-08-20	CI
Qingdao Yuanjia Medical Treatment Technology Co., Ltd. agreed to acquire 12.36% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd. for CNY140 million.	23-08-20	CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd announced that it expects to receive CNY 278.385575 million in funding from Qingdao Huilong Huaze Investment Co., Ltd.	23-08-17	CI
Yongxin Huarui Proposes Board and Supervisory Board Nominations for Hangzhou Tianmushan's Board	23-05-14	CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-25	CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Auditor Raises 'Going Concern' Doubt	23-04-24	CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-30	CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-30	CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29	CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-29	CI
Hangzhou Tianmushan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-24	CI
Hangzhou Tianmushan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-29	CI
Hangzhou Tianmushan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-29	CI
Yongxin Huarui Cultural Development Co., Ltd. completed the acquisition of 20.53% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Zhejiang Qingfeng Original Culture Co., Ltd.	20-12-16	CI

Chart Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd

Duration

Period

Chart Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd

More charts

Company Profile

Hangzhou TianMuShan Pharmaceutical Enterprise Co., Ltd is a China based company principally engaged in the research and development, production and sales of pharmaceuticals and related health products. The Company is mainly engaged in the manufacture of chemical drug substances, processing of Chinese herbal pieces as well as the manufacture of traditional Chinese medicine preparation and Western medicine. The Company's main products are bright eye drops, FufangXianzhuliYe, amoxicillin and clavulanate potassium tablets, Hechedazao Jiaonang, Liu Wei Di Huang oral liquid, menthol, and peppermint oil. The Company mainly operates its business in the domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-27 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HANGZHOU TIANMUSHAN PHARMACEUTICAL ENTERPRISE CO.,LTD	-23.76%	149M
ELI LILLY AND COMPANY	+26.57%	661B
NOVO NORDISK A/S	+27.55%	566B
JOHNSON & JOHNSON	-6.32%	352B
MERCK & CO., INC.	+20.46%	332B
ABBVIE INC.	+3.55%	283B
ASTRAZENECA PLC	+14.30%	231B
NOVARTIS AG	+5.21%	200B
ROCHE HOLDING AG	-9.04%	195B
AMGEN INC.	-4.93%	145B